1.
Pediatr Blood Cancer
; 65(2)2018 Feb.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28988442
RESUMEN
We report the case of a 6-year-old female with xeroderma pigmentosum (XP) who developed a nonoperable scalp tumor, treated with anti-programmed cell death protein 1 (anti-PD-1) therapy (nivolumab). She presented with a sarcomatoid carcinoma of the scalp with bone lysis as well as vascular and meningeal contact. Nivolumab was initiated because it has emerged as a promising immunotherapy. We observed a dramatic tumor response with excellent tolerance. However, while on nivolumab therapy she developed two large skin melanomas and several squamous cell carcinomas, which have been resected. These results demonstrate that cancer immunotherapy in patients with XP can be impressive but complex and warrants further investigation.
Asunto(s)
Anticuerpos Monoclonales , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Xerodermia Pigmentosa/tratamiento farmacológico , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/efectos adversos , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/cirugía , Niño , Femenino , Neoplasias de Cabeza y Cuello/patología , Humanos , Melanoma/inducido químicamente , Melanoma/patología , Melanoma/cirugía , Neoplasias Primarias Secundarias/inducido químicamente , Neoplasias Primarias Secundarias/patología , Neoplasias Primarias Secundarias/cirugía , Nivolumab , Neoplasias Cutáneas/patología , Xerodermia Pigmentosa/patología
2.
J Dermatol
; 50(6): e179-e180, 2023 06.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36601708
3.
4.
Int J Dermatol
; 52(1): 90-2, 2013 Jan.
Artículo
en Inglés
| MEDLINE
| ID: mdl-23278614